Coronavirus Disease 2019 Convalescent Plasma Utilization in the United States: Data From the National Inpatient Sample

Evan M Bloch; Ruchika Goel; Xianming Zhu; Eshan U Patel; Shmuel Shoham; David J Sullivan; Kelly A Gebo; Arturo Casadevall; Aaron A R Tobian

doi:10.1093/cid/ciad185

Coronavirus Disease 2019 Convalescent Plasma Utilization in the United States: Data From the National Inpatient Sample

Clin Infect Dis. 2023 Jul 26;77(2):237-241. doi: 10.1093/cid/ciad185.

Authors

Evan M Bloch¹, Ruchika Goel^{1

2}, Xianming Zhu¹, Eshan U Patel¹, Shmuel Shoham³, David J Sullivan⁴, Kelly A Gebo³, Arturo Casadevall⁴, Aaron A R Tobian¹

Affiliations

¹ Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA.
² Simmons Cancer Institute at Southern Illinois University, Springfield, Illinois, USA.
³ Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
⁴ Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Abstract

Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) use between October and December 2020 was characterized using the National Inpatient Sample database. CCP was administered in 18.0% of COVID-19-associated hospitalizations and was strongly associated with older age and increased disease severity. There were disparities in the receipt of CCP by race and ethnicity, geography, and insurance.

Keywords: COVID-19; COVID-19 serotherapy; SARS-CoV-2; blood donors; blood transfusion.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Viral
COVID-19 Serotherapy
COVID-19* / therapy
Humans
Immunization, Passive
Inpatients
SARS-CoV-2
United States / epidemiology

Substances

Antibodies, Viral

Abstract

Publication types

MeSH terms

Substances

Grants and funding